Merck & Co. Inc.

ticker: MRK step: 01 generated: 2026-05-11 source: quick-research

Merck & Co., Inc. (MRK) — Business Overview

Business Description

Merck is one of the world's largest pharmaceutical companies, anchored by Keytruda (pembrolizumab) — the best-selling oncology drug in history ($29.5B in 2024 sales, projected ~$32.7B peak in 2026). The company sells branded pharmaceuticals, vaccines, and animal health products globally. Merck's strategic identity for 2026–28 is dominated by one question: how does it absorb the Keytruda patent cliff in 2028? Management is responding through (1) Keytruda subcutaneous (Keytruda QLEX) for IV-to-SC conversion, (2) splitting oncology into a standalone business unit, (3) aggressive M&A ($10B Verona + $6.7B Terns + smaller deals), and (4) accelerating WINREVAIR (PAH) and other pipeline launches.

Revenue Model

Single reportable segment ("Pharmaceutical"), but with several franchise groupings:

• Oncology — Keytruda (~45% of total revenue), Welireg, Lynparza (royalty from AZ partnership), Lenvima (royalty), and pipeline.
• Vaccines — Gardasil/Gardasil 9 (HPV), Pneumovax, ProQuad (MMRV), Vaxneuvance, Capvaxive (pneumococcal), Rotateq.
• Cardiovascular / Pulmonary — WINREVAIR (PAH), Ohtuvayre (COPD, post-Verona acquisition), Adempas (royalty), Verquvo, Bridion.
• Diabetes / Hospital Acute Care — Januvia/Janumet (off-patent), Bridion, Zerbaxa, Inhalation anesthesia.
• Antiviral / Other — Lagevrio (Covid), Isentress, Pifeltro.
• Animal Health — Companion animal + livestock pharmaceuticals (Bravecto, vaccines).

Revenue mix is heavily skewed to Keytruda — the single largest concentration risk in mega-cap pharma.

Products & Services

• Keytruda — PD-1 inhibitor approved in 40+ indications across 20+ tumor types; the cornerstone oncology asset.
• Keytruda QLEX — Subcutaneous pembrolizumab formulation (FDA approved); aims for 30–40% conversion by 2028.
• Welireg (HIF-2α) — Newer oncology asset (renal cell carcinoma).
• Gardasil 9 — HPV vaccine; China shipment freeze in 2025 was a multi-quarter drag.
• WINREVAIR — PAH (activin inhibitor); 12-yr US biologics exclusivity (potentially to 2037); $419M in 2024, ramping toward $5–10B peak.
• Ohtuvayre (ensifentrine) — First-in-class COPD maintenance; potential blockbuster from Verona acquisition (closed late 2025).
• Pipeline (selected): TIGIT/PD-1 (vibostolimab), MK-7264 (TL1A IBD), oral PCSK9 (Eylea-class), Terns CML asset, plus oncology pipeline rebuilding.

Customer Base & Go-to-Market

• Oncology: Hospitals, academic medical centers, oncology specialty pharmacies. ~30,000+ sales reps globally.
• Vaccines: Governments (Gardasil school-age programs), pediatricians, pharmacies, employers; large public-tender dependency.
• Animal Health: Veterinary clinics, livestock producers; distributed through veterinary distributors.
• Geography: ~50% US, ~50% international. China is critical for Gardasil (recovering); EU/Japan/EM for Keytruda and other oncology.

Competitive Position

• Oncology — Keytruda is the dominant PD-1 globally (~70%+ market share among PD-1s); Opdivo (BMS) is the primary competitor. Pipeline gap relative to competitors (Roche tiragolumab, BMS Opdivo subQ + relatlimab combo, AstraZeneca Imfinzi, Daiichi/AZ DXd ADCs) is the single biggest structural issue.
• Vaccines — Gardasil 9 is the global standard for HPV; ProQuad/MMR-V are best-in-class for childhood vaccines; new Capvaxive pneumococcal targets adults.
• PAH — WINREVAIR is best-in-class entry; competing with Opsumit (J&J) and Uptravi (J&J) but with novel MOA.
• Animal Health — Top 3 globally with Zoetis and Elanco.

Structural risks: (1) Keytruda 2028 patent cliff (US composition-of-matter expires); (2) ~$25B+ revenue at risk over 2028–32; (3) pipeline depth vs. peers; (4) IRA Medicare price negotiations expanded to more drugs starting 2026.

Key Facts

• Founded: 1891
• Headquarters: Rahway, New Jersey
• Employees: ~71,000
• Exchange: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Market Cap: ~$200B
• 2024 Revenue: $64.2B
• 2025 Revenue Guide: $64.1–65.6B
• Major Acquisitions Recent: Verona Pharma ($10B, Ohtuvayre COPD); Terns Pharma ($6.7B, CML); Prometheus ($10.8B, MK-7240 TL1A); Acceleron ($11.5B, WINREVAIR predecessor)

ticker: MRK step: 04 generated: 2026-05-11 source: quick-research

Merck & Co., Inc. (MRK) — Financial Snapshot

Income Statement Summary

*FY2023 GAAP EPS depressed by ~$10B Prometheus + ~$5.5B Daiichi-Sankyo IPR&D charges.

Top Products (FY2025)

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate)

• P/E: ~9x (FY25 adjusted EPS) | EV/EBITDA: ~8x | FCF Yield: ~6% (depressed by IPR&D charges)
• Revenue Growth (FY25): +1.3% | Adjusted EPS Growth: +17%
• Dividend Yield: ~2.9%; payout ratio ~44% of earnings
• Operating Margin: ~43% (adjusted)

Growth Profile

2025 was the last "clean" year before the 2028 Keytruda patent cliff dominates the narrative. Revenue +1.3% nominally (Gardasil China + Lagevrio Covid both significant drags); adjusted EPS +17% on operating leverage and lower charges. Key forward dynamics:

2026–27: Keytruda continues growing toward ~$32B+ peak (2026); Keytruda QLEX (subcutaneous) launching to convert IV patients ahead of biosimilars. WINREVAIR ramping; Ohtuvayre (from Verona) launching; pipeline asset readouts. ~$24B FCF target for 2027.

2028+: Keytruda US loss of exclusivity. Bear case: ~50%+ of Keytruda IV revenue lost over 2028–32 to biosimilars; revenue declines 15–25% from peak. Bull case: 30–40% conversion to Keytruda QLEX (12-yr biologic exclusivity) preserves $9–12B; pipeline (WINREVAIR, Ohtuvayre, MK-7240 TL1A, Terns CML, oral PCSK9) replaces lost revenue.

Forward Estimates

2026 Guide (initial):

• Revenue: $65.5–67B (vs. $67.6B consensus — modest miss)
• Adjusted EPS: $5.00–5.15 (vs. $5.36 consensus — includes ~$3.65 one-time Cidara acquisition charge)
• Underlying EPS (ex-Cidara charge): $8.65–8.80, roughly flat YoY

Sell-side estimates have material divergence on 2028+. Bull case: $24B+ FCF / share at 2027 trough, recovery to growth by 2030 via pipeline. Bear case: 2028–30 trough in EPS at ~$5–6/share with multiple compression to ~8x P/E.

ticker: MRK step: 12 generated: 2026-05-11 source: quick-research

Merck & Co., Inc. (MRK) — Investment Catalysts & Risks

Bull Case Drivers

1. Keytruda QLEX (subcutaneous) IV-to-SC conversion — Launched Q4 2025; if Merck converts 30–40% of Keytruda IV patients to QLEX (12-year biologics exclusivity through ~2037) by 2027, it preserves $9–12B of Keytruda revenue post-2028 biosimilar wave. The earliest IV biosimilars cannot match a fully-converted SC patient base.
2. WINREVAIR (PAH) blockbuster trajectory — $1.4B in FY25 (first full year); broker peak estimates $5–10B; 12-yr exclusivity to ~2037. Best-in-class activin inhibitor with novel MOA vs. PAH standard of care (Opsumit, Uptravi). Material WINREVAIR upside relative to consensus is the single largest pipeline driver to 2028+.
3. Ohtuvayre (COPD) post-Verona acquisition — $10B Verona deal acquired the first-in-class COPD maintenance therapy. Multi-billion peak potential in a large, underserved respiratory market.
4. Aggressive M&A war chest deploying — Verona ($10B) + Terns ($6.7B CML) + Cidara (~$9B charge in Q1 2026) + Prometheus ($10.8B MK-7240 TL1A IBD) + ongoing pipeline rebuilds. >$50B+ deployed since 2023 specifically targeting post-Keytruda revenue gap.
5. Animal Health steady mid-single-digit growth — $6.4B in FY25 (+8%); structurally less cyclical and less patent-dependent than human pharma. Possible spin-off optionality (Pfizer Zoetis precedent).
6. Adjusted operating margin at 43% with operating leverage — Best-in-class pharma operating margin. As pipeline assets launch, operating leverage compounds.
7. Valuation reset already priced in (~9x P/E) — MRK trades at a meaningful discount to peers (J&J ~17x, LLY ~50x). The Keytruda cliff is largely priced in; positive surprises (faster QLEX conversion, larger WINREVAIR peak, pipeline readouts) re-rate.

Bear Case Risks

1. 2028 Keytruda patent cliff — ~$25B+ revenue at risk — Largest single-product patent cliff in pharma history. US composition-of-matter expires 2028; EU 2030. Multiple biosimilars filed (Korea, India, China); FDA biosimilar approvals expected 2028–29.
2. Pipeline depth gap vs. peers — Despite >$50B in M&A, Merck's late-stage non-Keytruda pipeline is thinner than peers (LLY, NVO, AZN). Replacement revenue trajectory remains uncertain.
3. 2026 guidance disappointment — Initial 2026 revenue guide ($65.5–67B) below consensus ($67.6B); EPS guide includes ~$3.65 in Cidara charges. Suggests management's confidence in near-term growth is constrained.
4. Gardasil China + global HPV exposure — Multi-quarter Gardasil shipment freeze in China + slowing global HPV demand (already-vaccinated cohorts; demographic headwinds). Gardasil was a ~$9B run-rate franchise now at $8.2B and declining.
5. IRA Medicare price negotiations — Keytruda eligible for negotiation in 2028 (small-molecule status to be litigated re biologics). Multiple smaller drugs already subject to negotiation. Pricing pressure structural.
6. Pipeline single-asset readout risk — MK-7240 (TL1A IBD from Prometheus), oral PCSK9, vibostolimab (TIGIT), and Terns CML asset all have material binary readouts through 2026–28. Failures dent the post-Keytruda growth narrative.
7. M&A integration risk — Multiple large acquisitions in flight (Verona, Terns, Cidara) layered onto Prometheus and Acceleron — operational complexity is non-trivial.

Upcoming Events

• Q2 2026 earnings (late July 2026): Keytruda QLEX conversion rates + WINREVAIR + 2026 guide check.
• Keytruda QLEX adoption metrics: Quarterly disclosures from Q2 2026 onward.
• WINREVAIR label expansions: Multiple Phase 3 readouts in expanded PAH indications.
• Pipeline readouts: MK-7240 (TL1A IBD), vibostolimab (TIGIT), oral PCSK9, MK-1084.
• 2027 / 2028 Keytruda biosimilar filings: First competitive applications expected H2 2027.
• Cidara acquisition close + integration: Expected Q1–Q2 2026.
• Potential Animal Health spin-off: Possible strategic action through 2026–27.

Analyst Sentiment

Consensus rating is Buy / Overweight (~60% Buy, 35% Hold, 5% Sell). Price targets cluster $105–115 vs. trading ~$82–88 (~20–30% implied upside). Bull case targets ~$130 on Keytruda QLEX success + WINREVAIR blockbuster; bear case ~$70 on Keytruda cliff materializing without pipeline backstop. Bernstein, Morgan Stanley, BMO maintain Buy; UBS at Neutral; Goldman at Buy with target $115.

Research Date

Generated: 2026-05-11